Rektum Kanseri
Özet
Rektum kanseri, dünya genelinde yaygınlığı ve genç nüfustaki artış eğilimiyle önemli bir sağlık sorunudur. Hastalık; genetik faktörlerin yanı sıra obezite, diyabet, hareketsiz yaşam ve beslenme alışkanlıklarıyla ilişkilendirilmekte; tanı ise dijital rektal muayene, rektoskopi ve biyopsi ile konulmaktadır. Tedavi planlamasında doğru evreleme kritik önem taşırken, pelvik MRG en güvenilir görüntüleme yöntemi olarak kabul edilir. Erken evre vakalarda lokal eksizyon veya total mezorektal eksizyon (TME) cerrahisi tercih edilirken, laparoskopik ve robotik cerrahi teknikler de başarıyla uygulanmaktadır. Lokal ileri tümörlerde ameliyat öncesi neoadjuvan kemoradyoterapi standart bir yaklaşım haline gelmiştir. Cerrahi yöntemler arasında Low Anterior Rezeksiyon (LAR) ve anal sfinkter tutulumunda Abdomino-perineal Rezeksiyon (APR) öne çıkar. Son yıllarda klinik tam yanıt veren hastalarda "İzle ve Bekle" protokolü gibi ameliyatsız yönetim seçenekleri tartışılmakta, metastatik vakalarda ise palyatif ve küratif tedaviler multimodalite yaklaşımlarıyla dengelenmektedir. Tedavi sonrası ilk iki yıl yakın takip, nükslerin erken tespiti ve komplikasyon yönetimi açısından hayatidir.
Rectal cancer remains a significant global health challenge, characterized by a rising incidence among younger populations and a multifaceted etiology involving lifestyle factors such as obesity, diabetes, and dietary habits. Diagnosis is primarily achieved through digital rectal examination, rectoscopy, and biopsy, while pelvic MRI serves as the definitive staging tool for assessing tumor depth and mesorectal fascia involvement. Treatment strategies are highly individualized; early-stage tumors are managed with local excision or radical total mesorectal excision (TME) via open, laparoscopic, or robotic techniques, whereas locally advanced cases require neoadjuvant chemoradiotherapy. Surgical options range from Low Anterior Resection (LAR), aimed at preserving sphincter function, to Abdominoperineal Resection (APR) for tumors involving the anal apparatus. Recent advancements have introduced the "Watch and Wait" protocol for patients achieving a complete clinical response, offering a non-operative alternative under stringent monitoring. In metastatic scenarios, multimodal therapies are leveraged to balance symptom control with curative potential. Long-term management necessitates rigorous follow-up, particularly during the first two years, to monitor for recurrence and manage post-operative complications such as anastomotic leaks or functional impairments.
Referanslar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.doi: 10.3322/caac.21442.
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.doi: 10.1002/ijc.31937.
Glynne-Jones R, Wyrwicz L, Tiret E. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl 4): iv22-40. PMID: 2888. 1920.doi: 10.1093/annonc/mdx224.
Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer. 2004;108(3):433-442.doi: 10.1002/ijc.11540.
Aleksandrova K, Pischon T, Jenab M, et al. Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. BMC Med. 2014;12(1):168.doi: 10.1186/s12916-014-0168-4.
Kirkegaard H, Johnsen NF, Christensen J, et al. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ. 2010;341:c5504.doi: 10.1136/bmj.c5504.
Murphy N, Norat T, Ferrari P, et al. Dietary fibre intake and risks of cancers of the colon and rectum in the European prospective investigation into cancer and nutrition (EPIC). PloS one. 2012;7(6):e39361.doi: 10.1371/journal.pone.0039361.
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422.doi: 10.1093/annonc/mdw235.
Burdan F, Sudol-Szopinska I, Staroslawska E, et al. Magnetic resonance imaging and endorectal ultrasound for diagnosis of rectal lesions. Eur J Med Res. 2015;20(1):4.doi: 10.1186/s40001-014-0078-0.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours: John Wiley & Sons; 2017.
Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging–detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. Journal of Clinical Oncology. 2011;29(28):3753-3760.doi: 10.1200/JCO.2011.34.9068.
Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Annals of surgery. 2008;248(3):420-428.doi: 10.1097/SLA.0b013e3181859f71.
Liu Y, Wang R, Ding Y, et al. A predictive nomogram improved diagnostic accuracy and interobserver agreement of perirectal lymph nodes metastases in rectal cancer. Oncotarget. 2016;7(12):14755-14764.doi: 10.18632/oncotarget.7548.
Stornes T, Wibe A, Nesbakken A, et al. National Early Rectal Cancer Treatment Revisited. Dis Colon Rectum. 2016;59(7):623-629.doi: 10.1097/DCR.0000000000000591.
Stevenson AR, Solomon MJ, Lumley JW, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. JAMA. 2015;314(13):1356-1363.doi: 10.1001/jama.2015.12009.
Fleshman J, Branda M, Sargent DJ, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA. 2015;314(13):1346-1355.doi: 10.1001/jama.2015.10529.
Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767-774.doi: 10.1016/S1470-2045(14)70205-0.
São Julião GP, Habr-Gama A, Vailati BB, et al. New strategies in rectal cancer. Surgical Clinics. 2017;97(3):587-604.doi: 10.1016/j.suc.2017.01.008.
Penna M, Cunningham C, Hompes R. Transanal total mesorectal excision: why, when, and how. Clinics in colon and rectal surgery. 2017;30(05):339-345.doi: 10.1055/s-0037-1606111.
McMurrick PJ, Oliva K, Carne P, et al. The first 1000 patients on an internet-based colorectal neoplasia database across private and public medicine in Australia: development of a binational model for the Colorectal Surgical Society of Australia and New Zealand. Dis Colon Rectum. 2014;57(2):167-173.doi: 10.1097/DCR.0000000000000041.
Hawkins AT, Albutt K, Wise PE, et al. Abdominoperineal Resection for Rectal Cancer in the Twenty-First Century: Indications, Techniques, and Outcomes. J Gastrointest Surg. 2018;22(8):1477-1487.doi: 10.1007/s11605-018-3750-9.
Ishihara S, Kanemitsu Y, Murono K, et al. Oncological benefit of lateral pelvic lymph node dissection for rectal cancer treated without preoperative chemoradiotherapy: a multicenter retrospective study using propensity score analysis. International journal of colorectal disease. 2016;31(7):1315-1321.doi: 10.1007/s00384-016-2607-5.
Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003;227(2):371-377.doi: 10.1148/radiol.2272011747.
Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. The Lancet. 2009;373(9666):821-828.doi: 10.1016/S0140-6736(09)60485-2.
Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Annals of surgery. 2011;253(4):711-719.doi: 10.1097/SLA.0b013e31820b8d52.
Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32(1):34-43.doi: 10.1200/JCO.2012.45.3258.
Brændengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. Journal of clinical oncology. 2008;26(22):3687-3694.doi: 10.1200/JCO.2007.15.3858.
Sauer R, Becker H, Hohenberger W. Preoperative versus Postoperative CRT for Rectal Cancer. The German Rectal Cancer Study Group. N Engl J Med. 2004;351:1731-1740.doi: 10.1056/NEJMoa040694.
Mulsow J, Winter DC. Sphincter preservation for distal rectal cancer-a goal worth achieving at all costs? World journal of gastroenterology: WJG. 2011;17(7):855.doi: 10.3748/wjg.v17.i7.855.
Hendren SK, O'Connor BI, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Annals of surgery. 2005;242(2):212.doi: 10.1097/01.sla.0000171299.43954.ce.
Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53(12):1692-1698.doi: 10.1007/DCR.0b013e3181f42b89.
Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711-717; discussion 717-718.doi: 10.1097/01.sla.0000141194.27992.32.
Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(12):825-836.doi: 10.1016/S2468-1253(18)30301-7.
van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537-2545.doi: 10.1016/S0140-6736(18)31078-X.
Dattani M, Heald RJ, Goussous G, et al. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. Ann Surg. 2018;268(6):955-967.doi: 10.1097/SLA.0000000000002761.
Parmar K, Malcomson L, Renehan AG. Watch and wait or surgery for clinical complete response in rectal cancer: a need to study both sides. 2019.
Keller DS, Berho M, Perez RO, et al. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17(7):414-429.doi: 10.1038/s41575-020-0275-y.
Wilkinson N. Management of Rectal Cancer. Surg Clin North Am. 2020;100(3):615-628.doi: 10.1016/j.suc.2020.02.014.
